Elsevier Offers First Consult Users Anywhere, Anytime Access Through New Apple iPhone App
New iPhone App gives clinicians, students and others access to trusted, quick, on-demand answers from First Consult, without a data connection
NEW YORK, NY – November 16, 2010 – Elsevier, the leading publisher of scientific, technical and medical information products and services, today announced the availability of an iPhone App that gives whenever, wherever access to users of First Consult, an online clinical information resource that delivers quick, trusted answers to clinical questions at the point-of-care. The app is available as a free download from the Apple App Store and works on Apple’s iPhone, iPad, and iPod Touch devices. Access is available to all First Consult individual and institutional subscribers as part of the subscription for no additional charge. Free 60-day trial evaluations are also available.
Individuals who download the app by January 31, 2011, automatically are entered into a drawing to win an iPad. In addition, the institution with the most downloads of the app by the same date will be awarded an iPad for library use.
Developed in partnership with the mobility team within the Information Services practice at Infosys, the new First Consult App supports physicians, residents and medical students who may lack an immediate data connection within a hospital, office or medical school but who still need instant, user-friendly access to the latest information on patient evaluation, diagnosis, clinical management, prognosis, and prevention from First Consult.
“iPhone access to First Consult fulfills Elsevier’s commitment to provide clinicians with on-demand access to accurate, evidence-based and actionable information when and where it’s needed in the healthcare workflow,” said Chris Dillon, Managing Director for Clinical Decision Support at Elsevier Health Sciences. “Our mobile app will be indispensable in helping clinicians throughout the world reduce risks for medical errors, adverse drug events and extended lengths of stay.”
In addition to offering clinicians anytime/anywhere access to clinical content, the First Consult iPhone App saves time thanks to its easy-to-use, easy-to-learn navigation. Because data is stored on the mobile device, clinicians no longer need to wait for data pages to load.
“The new First Consult App is a convenient, easy-to-use, time-saving tool for busy clinicians who need a fast, trusted answer on a patient question, wherever they are and whenever they need it—whether in the hospital, the office, at home or in the car,” said Jonathan Teich M.D., Chief Medical Informatics Officer, Elsevier. “It enables better decision-making because clinicians can be confident that they’ve received the best, most regularly updated information on patient evaluation, diagnosis, treatment, tests and prevention.”
The release of the First Consult iPhone App coincides with physicians’ growing interest in mobile devices. Sixty-four percent of physicians owned smartphones in 2009, a figure that is expected to reach 81 percent by 2012, according to Manhattan Research. Moreover, 94 percent of physicians who own smartphones use them to communicate, manage personal and business workflows, and access medical information, says a 2010 survey from Spyglass Consulting Group.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media Contact
Vice President of Global Relations, Elsevier